SB6 Alabama 2012 1st Special Session

Summary

Primary Sponsor

Arthur OrrSenator

Republican

Co-Sponsors

Bill HoltzclawClay Scofield

Session

First Special Session 2012

Title

County or municipality, authorities, lease of property to United States, powers of authority expanded, expenditure of funds to promote federal facilities authorized, Sec.11-101A-8 am'd

Summary

The Abortion-Inducing Drug Safety Act would regulate how abortion-inducing drugs are used, requiring doctor exams, FDA-approved protocols, follow-up, and reporting, with penalties for providers who don't comply.

What This Bill Does

If passed, the bill would require an in-person physician exam before administering any abortion-inducing drug and require treatment under FDA-tested protocols with proper documentation and follow-up. It would mandate specific provider duties (drug labeling, emergency-to-hospital arrangements, and follow-up visits around two weeks) and require reporting of any adverse events to the FDA and the state Department of Public Health. Violations could lead to criminal penalties for providers, and there would be civil, professional, and wrongful death remedies, while protecting pregnant women from criminal penalties and not creating a right to abortion.

Who It Affects

• Pregnant women seeking abortion-inducing drugs, who would be examined in person, receive follow-up care, and have privacy protections, with criminal penalties not applied to the woman.
• Physicians and other abortion providers/clinics, who would must follow strict protocols (in-person exams, FDA protocol adherence, documentation, emergency arrangements, follow-up, and adverse-event reporting) and could face criminal, civil, or professional disciplinary actions for noncompliance.

Key Provisions

• Establishes the Abortion-Inducing Drug Safety Act to regulate the use of abortion-inducing drugs.
• Defines key terms (abortion, abortion-inducing drug, physician, medical abortion, mifepristone) and clarifies the department and labeling requirements.
• Requies in-person examination by a physician before providing abortion-inducing drugs and documentation of gestational age and intrauterine location.
• Requires administration of abortion-inducing drugs only under FDA-tested protocol, with patient labeling, emergency-handling arrangements, and a planned follow-up at about 14 days.
• Mandates reporting of adverse events to the FDA and the Department within three days.
• Imposes criminal penalties for violators (Class C felony) and provides civil damages, professional discipline, and wrongful death remedies; provides no penalties for the pregnant woman.
• Contains privacy protections for patients and states the act does not create a right to abortion; includes severability and a 90-day effective date.
• Excludes the bill from certain local-expenditure requirements under Amendment 621 because it creates a new crime or amends the definition of an existing crime.

AI-generated summary using openai/gpt-5-nano on Feb 24, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Authorities